文献速递核素与放射性配体治疗

肝细胞癌钇-90树脂微球放射栓塞治疗后基于三维体素剂量学分析

Post-treatment three-dimensional voxel-based dosimetry after Yttrium-90 resin microsphere radioembolization in HCC.
PubMed 文献 · EJNMMI Res · 2022-02-04

本研究对30例肝细胞癌(HCC)患者的36次选择性内放射治疗(SIRT)、共43个病灶进行治疗后[90Y] PET/CT三维体素剂量学分析,评估剂量-效应关系。肿瘤吸收剂量≥120 Gy组疾病控制率79%,低于<120 Gy组的53%;≥120 Gy组中位总生存期(OS)33个月、中位无进展生存期(PFS)23个月,均长于<120 Gy组(OS 17个月、PFS 13个月)。结论认为较高的三维体素肿瘤吸收剂量与4个月疾病控制及更长的OS和PFS相关。

要点

  • 肿瘤吸收剂量≥120 Gy组疾病控制率79%,<120 Gy组为53%。
  • 预测疾病控制的平均肿瘤吸收剂量最佳截断值为131 Gy。
  • ≥120 Gy组中位OS 33个月、中位PFS 23个月,均长于<120 Gy组(OS 17个月、PFS 13个月)。

核心结论

  • HCC患者较高的三维体素肿瘤吸收剂量与4个月疾病控制及更长的OS和PFS相关。
  • [90Y] SIRT中的剂量体积直方图(DVH)可能在评估性剂量学中发挥作用。

研究设计与样本

  • 对接受SIRT治疗的HCC患者进行治疗后[90Y] PET/CT剂量学分析,共30例患者、36次SIRT治疗、43个病灶。
  • 根据平均肿瘤吸收剂量将治疗病灶分为<120 Gy组(n=15)和≥120 Gy组(n=28)。
  • 从DVH计算肿瘤吸收剂量、肿瘤体积接受≥100、150、200或250 Gy的平均百分比(V),以及肿瘤体积30%、50%、70%和90%接受的平均最小吸收剂量(D)。

主要发现

  • ≥120 Gy组中位肿瘤吸收剂量为207 Gy(IQR 154-311 Gy),<120 Gy组为62 Gy(IQR 49-97 Gy),差异有统计学意义(p<0.01)。
  • 疾病控制率在≥120 Gy组为79%,<120 Gy组为53%。
  • 预测疾病控制的平均肿瘤吸收剂量最佳截断值为131 Gy。
  • 平均肿瘤吸收剂量120 Gy时肿瘤控制概率为54%(95%CI 52-54%),284 Gy时为90%(95%CI 87-92%)。
  • 仅D30在疾病控制与进展性疾病之间差异有统计学意义(p=0.04)。

关键数值与推荐

  • 以平均肿瘤吸收剂量120 Gy为界分组:≥120 Gy组n=28,<120 Gy组n=15。
  • 预测疾病控制的平均肿瘤吸收剂量最佳截断值为131 Gy。
  • 平均肿瘤吸收剂量120 Gy时肿瘤控制概率54%(95%CI 52-54%),284 Gy时90%(95%CI 87-92%)。
  • 仅D30在疾病控制与进展性疾病间差异有统计学意义(p=0.04)。

临床怎么用

  • 治疗后[90Y] PET/CT剂量学目前被推荐用于验证治疗计划,因[99mTc] MAA SPECT/CT常难以预测后续实际[90Y]吸收剂量。
  • 作者认为[90Y] SIRT中的DVH可能在评估性剂量学中发挥作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Post-therapy [90Y] PET/CT-based dosimetry is currently recommended to validate treatment planning as [99mTc] MAA SPECT/CT is often a poor predictor of subsequent actual [90Y] absorbed dose. Treatment planning software became available allowing 3D voxel dosimetry offering tumour-absorbed dose distributions and dose-volume histograms (DVH). We aim to assess dose-response effects in post-therapy [90Y] PET/CT dosimetry in SIRT-treated HCC patients for predicting overall and progression-free survival (OS and PFS) and four-month follow-up tumour response (mRECIST). Tumour-absorbed dose and mean percentage of the tumour volume (V) receiving ≥ 100, 150, 200, or 250 Gy and mean minimum absorbed dose (D) delivered to 30%, 50%, 70%, and 90% of tumour volume were calculated from DVH's. Depending on the mean tumour -absorbed dose, treated lesions were assigned to a < 120 Gy or ≥ 120 Gy group. RESULTS: Thirty patients received 36 SIRT treatments, totalling 43 lesions. Median tumour-absorbed dose was significantly different between the ≥ 120 Gy (n = 28, 207 Gy, IQR 154-311 Gy) and < 120 Gy group (n = 15, 62 Gy, IQR 49-97 Gy, p <0 .01). Disease control (DC) was found more frequently in the ≥ 120 Gy group (79%) compared to < 120 Gy (53%). Mean tumour-absorbed dose optimal cut-off predicting DC was 131 Gy. Tumour control probability was 54% (95% CI 52-54%) for a mean tumour-absorbed dose of 120 Gy and 90% (95% CI 87-92%) for 284 Gy. Only D30 was significantly different between DC and progressive disease (p = 0.04). For the ≥ 120 Gy group, median OS and PFS were longer (median OS 33 months, [range 8-33 months] and median PFS 23 months [range 4-33 months]) than the < 120 Gy group (median OS 17 months, [range 5-33 months] and median PFS 13 months [range 1-33 months]) (p < 0.01 and p = 0.03, respectively). CONCLUSIONS: Higher 3D voxel-based tumour-absorbed dose in patients with HCC is associated with four-month DC and longer OS and PFS. DVHs in [90Y] SIRT could play a role in evaluative dosimetry.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Veenstra EB, Ruiter SJS, de Haas RJ, et al. Post-treatment three-dimensional voxel-based dosimetry after Yttrium-90 resin microsphere radioembolization in HCC. EJNMMI Res. 2022. PMID: 35122166. doi:10.1186/s13550-022-00879-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。